-
Macroeconomic Analysis
Iceland PESTLE Insights – A Macroeconomic Outlook Report
Iceland PESTLE Insights Report Overview The GDP of Iceland was estimated to be $31 billion in 2023 and the country ranked 20th out of 153 nations in the GCRI Q3 2023. As of February 2024, the Icelandic government has announced plans to address issues related to applicants for international protection, refugees, and immigrants through comprehensive policy management and increased coordination between ministries and institutions. The objectives include more efficient regulations and services, promotion of equal opportunities, better utilization of human...
-
Sector Analysis
Denmark Statutory and Private Employee Benefits, 2024 Update
Denmark Statutory and Private Employee Benefits Report Overview Danish social security operates a societal model in which the state assumes primary responsibility for the welfare of its citizens. It covers benefits such as hospitalization, sickness, and maternity benefits; benefits regarding accidents at work and occupational diseases; funeral expenses; disability pension; old-age and supplementary pensions; family benefits; and unemployment benefits. Denmark is among the few countries in the world, which adjusted to the challenge of providing its citizens with a flexible...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Blinatumomab in B-Cell Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Blinatumomab in B-Cell Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Blinatumomab in B-Cell Leukemia Drug Details: Blinatumomab (Blincyto) is a bi-specific monoclonal antibody acts...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Blinatumomab in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Blinatumomab in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Blinatumomab in Chronic Lymphocytic Leukemia (CLL) Drug Details: Blinatumomab (Blincyto)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Blinatumomab in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Blinatumomab in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Blinatumomab in Follicular Lymphoma Drug Details: Blinatumomab (Blincyto) is a bi-specific monoclonal antibody acts...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Blinatumomab in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Blinatumomab in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Blinatumomab in Marginal Zone B-cell Lymphoma Drug Details: Blinatumomab (Blincyto)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Blinatumomab in Nodal Marginal Zone B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Blinatumomab in Nodal Marginal Zone B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Blinatumomab in Nodal Marginal Zone B-Cell Lymphoma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Blinatumomab in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Blinatumomab in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Blinatumomab in Extranodal Marginal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Blinatumomab in Splenic Marginal Zone B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Blinatumomab in Splenic Marginal Zone B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Blinatumomab in Splenic Marginal Zone B-Cell Lymphoma Drug...
-
Analyst Opinions
Gender Identity – Consumer TrendSights Analysis, 2023
Gender Identity - Consumer TrendSights Report Overview The fluidity between stereotypical gender roles is growing and traditional gender-targeting marketing strategies are becoming less effective. Hence, the popularity of vanishing gender-assigned roles need to be addressed to meet consumers' demands and extend audience. Consumers are redefining and challenging conventional division between gender roles, thus blurring the boundaries between "for him" and "for her" products. TrendSights Framework: Gender Identity Buy the Full Report for More Insights into the Gender Identity Consumer TrendSights...